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Background: There are increasing data for troponin (Tn) measured with a high sensitivity (hs) assay for prognosis in patients (pts) with acute 
and chronic heart failure (HF). This sensitive marker of myocyte injury could augment or supplant established markers of myocardial stretch and 
inflammation for diagnosis and prognosis of patients with HF. We hypothesized that hsTnI identified pts with acute HF and was a stronger prognostic 
marker than NT-proBNP or serum ST2 (sST2).
Methods: 410 pts with acute dyspnea at 5 centers were tested with NT-proBNP, ST2 and hs cTnI (Siemens, VISTA research assay) upon presentation 
to the emergency department. The diagnosis of acute HF was independently adjudicated and pts were followed for one-year for all-cause mortality.
Results: The mean age was 57+/-14 , with 157 (39%) females and 259(64%) African Americans. 146 pts were diagnosed with HF. The area under 
the curve for HF diagnosis was 0.91 for NT-proBNP, 0.71 for ST2 and 0.834 for hs cTnI (P< 0.001 for ST2 and hs cTnI vs. NT-proBNP). At one-year 
51(12%) pts had died. Biomarker levels and hazard ratio for death per log unit of each biomarker are shown in Table. hsTnI level is a univariate 
predictor of outcome, but once ST2 levels are included in a model it is no longer significant.
Conclusions: NT-proBNP is a superior diagnostic test to hsTnI for identifying dyspnea pts with HF. All biomarkers were prognostic. However, only 
ST2, but not hsTnI or NT-proBNP, remains a significant predictor for all-cause mortality in a multivariate model. 
Biomarker Died Alive Unadjusted HR (95% CI) Adjusted HR (95% CI)
NT-proBNP (pg/mL) 2209 (306,10914) 278 (34, 2603)* 1.3 (1.1-1.4) 0.89 (0.73-1.1)
ST2 (U/mL) 71.3 (39.5,135.0) 36.3 (25.2,58.6)* 2.9 (2.0-4.0) 3.1 (2.0-4.7)
hs cTnI (pg/mL) 21.8 (7.5, 66.9) 11.6 (2.9, 38.6)* 1.2 (1.1-1.4) 1.0 (0.82-1.3)
CI, confidence interval; HR, hazard ratio. Values shown as the median (inter-quartile range) . Adjusted model includes: age, eGFR and all three 
biomarkers. *P< 0.001 for alive versus died
